Abstract
While advances in cancer treatment have improved the prognosis of cancer patients, the increasing number of cases of cancer associated with cardiovascular disease has increased the chances of receiving tumor cardiovascular support in the acute phase of cancer treatment. However, the response to late complications that appear more than 5-10 years after the end of cancer treatment in cancer survivors is by no means sufficient. Moreover, late cardiotoxicity often follows a serious clinical course when it develops potentially, and there are many cases in which it is difficult to deal with it.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
